GSK (GSK) Completes $950M Acquisition to Expand Drug Pipeline

GSK plc (NYSE:GSK) ranks among the best low-risk investments in May 2026. GSK plc (NYSE:GSK) stated on April 15 that it had completed the acquisition of 35Pharma Inc., a private clinical-stage biopharmaceutical firm based in Canada. The $950 million purchase gives GSK plc (NYSE:GSK) complete control of 35Pharma and its pipeline, which includes HS235, a chemical being developed for the treatment of pulmonary hypertension.

Pixabay/Public Domain

The statement claims that HS235 is designed for improved selectivity, potentially reducing the risk of bleeding and other side effects related to existing treatments for pulmonary arterial hypertension. Early clinical trials showed metabolic advantages such as fat-selective weight reduction, lean mass retention, and enhanced insulin sensitivity.

In a separate development, GSK plc (NYSE:GSK) announced that its prototype targeted cancer medicine Mo-rez had breakthrough potential after preliminary data indicated that it helped reduce tumors in patients with more advanced, difficult-to-treat cancers.

The number of patients who obtained a substantial decrease in tumor size, measured as at least a 30% shrinking, was the first indicator of success. In platinum-resistant ovarian cancer, 62% of patients reached this threshold, compared to 67% in endometrial cancer.

GSK plc (NYSE:GSK) is a UK-based global biopharmaceutical company that researches, develops, and sells medicines and vaccines for infectious diseases, HIV, respiratory conditions, cancer, and immune-related disorders.

While we acknowledge the risk and potential of GSK as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than GSK and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.